Stephen P. Dale, M.D., serves as Chief Medical Officer at Syncromune, where he leads the clinical development of the SYNC-T platform. He provides strategic medical oversight for the company’s expanding pipeline, shapes the clinical, regulatory, and translational roadmap, and ensures patient-centered advancement of innovative therapies.

Dr. Dale brings more than 20 years of global oncology research and development leadership, with deep expertise across biotechnology and large pharmaceutical organizations. His track record includes guiding early- and late-stage clinical programs, translational strategies, pivotal trial design, first-in-class dose optimization, and IND-enabling studies in alignment with FDA and EMA guidance, contributing to multiple regulatory approvals in solid tumors, hematological malignancies, immuno-oncology, precision oncology, and rare diseases.

Prior to joining Syncromune in January 2026, Dr. Dale served as Head of R&D and Chief Medical Officer at Kura Oncology, where he advanced the company’s precision medicine pipeline in oncology. He previously held senior oncology R&D and clinical leadership roles at Kyowa Kirin and AstraZeneca, leading global development programs across diverse therapeutic areas.

Dr. Dale earned his Doctor of Medicine (M.D.) and MBChB degrees from the University of Manchester Medical School.

Kerri-Ann Millar, CPA, serves as Chief Financial Officer at Syncromune, where she leads the company’s financial strategy, strengthens operational finance, and supports the advancement of the SYNC-T platform—a potentially first-in-class in situ combination immunotherapy for metastatic solid tumors, including metastatic castration-resistant prostate cancer (mCRPC).

With over 20 years of financial leadership in the life sciences and biotechnology sector, Ms. Millar brings a proven track record of guiding public and emerging companies through transformative growth phases, including initial public offerings (IPOs), capital raises exceeding $300 million, clinical development milestones, and commercialization efforts.

Prior to joining Syncromune in 2025, she served as Chief Financial Officer at Cue Biopharma, a publicly traded immunotherapy company, where she oversaw finance, investor relations, human resources, and IT functions while leading key financing transactions, including the company’s IPO.

She previously held senior financial leadership roles at Flexion Therapeutics, supporting its IPO, clinical advancement, and successful commercial launch, and at Curis, Inc., where she managed Sarbanes-Oxley compliance and SEC reporting requirements.

Ms. Millar began her career in public accounting at PricewaterhouseCoopers. She holds a B.S. in Accounting from Boston University and is a Certified Public Accountant in the Commonwealth of Massachusetts.

Gerald L. Andriole, Jr., M.D. was most recently  Professor and Director of Urology at Johns Hopkins University in the National Capital Region, retiring in June 2023. Previously, he had been the Royce Distinguished Professor and Chief of Urologic Surgery at Washington University in St. Louis for over 20 years.

Dr. Andriole has significant expertise in prostate cancer screening, prevention and treatment. He was continuously funded by NIH from 1993-2021 and has contributed over 450 peer-reviewed publications (H-index of 112).   He chaired the Prostate Committee of NCI’s PLCO Cancer Screening Trial and led the international REDUCE Prostate Cancer Chemoprevention Trial.  He also chaired the Prostate Committee of the Society of Urologic Oncology Clinical Trials Consortium.

Dr. Andriole is an elected member of the American Surgical Association, American Association of Genitourinary Surgeons, and the Clinical Society of Genitourinary Surgeons.  He received the Outstanding Achievement Award from the Urologic Oncology Branch of NCI, the Distinguished Clinician Award from Washington University, the Distinguished Alumni Award from Jefferson Medical College and the Williams Award for Prostate Cancer Research Excellence from the American Urologic Association Urology Care Foundation.

Dr. Andriole participated in the 5-year accelerated medical program at Penn State University and Jefferson Medical College, Philadelphia, PA. He trained in surgery at Strong Memorial Hospital, University of Rochester, NY and completed urology residency at Brigham and Women’s Hospital, Harvard Medical School, Boston, MA. He served a fellowship in Urologic Oncology at the National Cancer Institute of NIH in Bethesda, Maryland prior to joining the faculty at Washington University.

Dr. Mautino is a senior R&D executive and translational scientist with diverse experience in drug discovery and development, including strategic planning, program management, and intellectual property management. He brings 25+ years of experience in the fields of immuno-oncology, immunology, basic research, medicinal chemistry, bioassays, pharmacology, toxicology, safety pharmacology, clinical pharmacology, IND filings, regulatory guidelines, quality, pharmaceutical development, and drug substance and drug product manufacturing.

He has led multiple research projects related to design of vaccines, and research of combinations of therapeutic modalities in different cancer models including chemotherapy, radiation, vaccination, inhibition of metabolic, and other immune checkpoints.